# Chemoradiation Treatment for Head and Neck Cancer

> **NCT00704639** · PHASE1,PHASE2 · COMPLETED · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 60 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Carboplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00704639
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704639, "Chemoradiation Treatment for Head and Neck Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00704639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*